title: Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
authors.forename: C
authors.initials: C
authors.lastname: Chan
authors.forename: A
authors.initials: A
authors.lastname: Bartolucci
authors.forename: D
authors.initials: D
authors.lastname: Brenner
authors.forename: C
authors.initials: C
authors.lastname: Presant
authors.forename: E
authors.initials: E
authors.lastname: Davila
authors.forename: J
authors.initials: J
authors.lastname: Carpenter
authors.forename: F A
authors.initials: FA
authors.lastname: Greco
authors.forename: G
authors.initials: G
authors.lastname: Clamon
authors.forename: J
authors.initials: J
authors.lastname: Moore
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D001859:Bone Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; D009279:Naphthacenes; C029108:diaziquone